2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol

Journal of the American College of Cardiology

Volumn 64, Issue 6, 2014, Pages 601-612

  Smith, Sidney C ^a   Grundy, Scott M ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

atherosclerosis; cardiovascular diseases; cholesterol; hydroxymethylglutaryl CoA reductase inhibitors; LDL; lipoproteins; risk assessment; risk factors

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LDL; LIPOPROTEINS; RISK FACTORS; RISK ASSESSMENT;

ADVISORY COMMITTEES; AMERICAN HEART ASSOCIATION; CARDIOLOGY; CHOLESTEROL; DRUG DELIVERY SYSTEMS; GOALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 84905709162     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.06.1159     Document Type: Review

References (34)

1. A.S. Go, D. Mozaffarian, V.L. Roger American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2013 update: a report from the American Heart Association Circulation 127 2013 e6 e245
2. N.J. Stone, J.G. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
3. R. Graham, M. Mancher, D.M. Wolman, S. Greenfield, and E. Steinberg Institute of Medicine. Clinical Practice Guidelines We Can Trust 2011 National Academies Press Washington, DC
4. M.D. Neuman, J.N. Goldstein, M.A. Cirullo, and J.S. Schwartz Durability of class I American College of Cardiology/American Heart Association clinical practice guideline recommendations JAMA 311 2014 2092 2100
5. D.C. Goff, D.M. Lloyd-Jones, and G. Bennett et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2935 2959
6. R.H. Eckel, J.M. Jakicic, and J.D. Ard et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2960 2984
7. National Heart, Lung, and Blood Institute. Management of blood cholesterol in adults: systematic evidence review from the Cholesterol Expert Panel. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/ser/. Accessed June 20, 2014.
8. G.H. Gibbons, S.B. Shurin, G.A. Mensah, and M.S. Lauer Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute Circulation 128 2013 1713 1715
9. P. Muntner, L.D. Colantonio, and M. Cushman et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations JAMA 311 2014 1406 1415
10. MESA. CAC score reference values. Available at: http://www.mesa-nhlbi. org/CACReference.aspx. Accessed June 20, 2014.
11. American College of Cardiology. 2013 Prevention Guidelines ASCVD Risk Estimator. Available at: http://www.cardiosource.org/en/Science-And-Quality/ Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx. Accessed June 20, 2014.
12. American Heart Association. 2013 Prevention Guidelines Tools CV Risk Calculator. Available at: http://my.americanheart.org/professional/ StatementsGuidelines/PreventionGuidelines/Prevention-Guidelines-UCM-457698- SubHomePage.jsp. Accessed June 20, 2014.
13. B. Mihaylova, J. Emberson, L. Blackwell Cholesterol Treatment Trialists' Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
14. F. Taylor, M.D. Huffman, and A.F. Macedo et al. Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
16. National High Blood Pressure Education Program The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2004 National Heart, Lung, and Blood Institute Bethesda, MD Report No: 04-5230
17. M.S. Brown, and J.L. Goldstein A receptor-mediated pathway for cholesterol homeostasis Science 4 232 1986 34 47
18. M.R. Law, N.J. Wald, and S.G. Thompson By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308 1994 367 372
19. P.W. Wilson, R.B. D'Agostino, D. Levy, H. Silberschatz, and W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
20. J.E. Rossouw, B. Lewis, and B.M. Rifkind The value of lowering cholesterol after myocardial infarction N Engl J Med 323 1990 1112 1119
21. C. Baigent, L. Blackwell, J. Emberson Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
22. S.M. Boekholdt, B.J. Arsenault, and S. Mora et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
23. J.C. LaRosa, S.M. Grundy, D.D. Waters Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
24. C. Baigent, A. Keech, P.M. Kearney Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
25. S.M. Boekholdt, G.K. Hovingh, and S. Mora et al. Very low levels of atherogenic lipoproteins and risk of cardiovascular events; a meta-analysis of statin trials J Am Coll Cardiol 2014 In press
26. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
27. S.M. Grundy, L. Wilhelmsen, and G. Rose et al. Coronary heart disease in high-risk populations: lessons from Finland Eur Heart J 11 1990 462 471
28. W.E. Boden, J.L. Probstfield, T. Anderson AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
29. E.A. Stein, D. Gipe, and J. Bergeron et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
30. C.M. Alexander, P.B. Landsman, S.M. Teutsch, S.M. Haffner Third National Health and Nutrition Examination Survey (NHANES III), National Cholesterol Education Program (NCEP) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older Diabetes 52 2003 1210 1214
31. T.J. Anderson, J. Grégoire, and R.A. Hegele et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
32. P.M. Ridker, and N.R. Cook Statins: new American guidelines for prevention of cardiovascular disease Lancet 382 2013 1762 1765
33. M.G. Silverman, M.J. Blaha, and H.M. Krumholz et al. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis Eur Heart J 2013 Dec 23 [E-pub ahead of print]
34. S.M. Grundy Age as a risk factor: you are as old as your arteries Am J Cardiol 83 1999 1455 1457